Drug Profile


Alternative Names: MK-1439; MK-1439-019

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antiretrovirals; Nitriles; Pyridones; Small molecules; Triazoles
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 23 Nov 2016 Merck Sharp & Dohme initiates the bioavailability phase I NOVUM trial in Healthy volunteers in USA (PO, Minitablet) (EudraCT2016-004728-48)
  • 16 Nov 2016 Phase-I clinical trials in HIV-1 infections (In volunteers) in Canada (PO) (EudraCT2016-004656-30)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-1-infections(Monotherapy, Treatment-naive) in Germany (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top